Arch Biopartners Inc. (ACHFF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arch Biopartners Inc. (ACHFF) trades at $0.60 with AI Score 38/100 (Grade D). Arch Biopartners Inc. is a Canadian biotechnology firm focused on developing novel drugs for acute kidney injury and organ damage. Market cap: $40.58M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ACHFF: ACHFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACHFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACHFF: 1/1 perspectives are bearish.
How is this calculated? →Arch Biopartners Inc. (ACHFF) Healthcare & Pipeline Overview
Arch Biopartners Inc. is a Canadian biotechnology company developing novel therapies for acute kidney injury and organ damage, with a focus on its lead drug candidate LSALT Peptide currently in Phase 2 clinical trials. The company operates within the competitive biotechnology sector, targeting unmet needs in kidney disease treatment.
What Is the Investment Thesis for ACHFF?
Arch Biopartners Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead drug candidate, LSALT Peptide, is in Phase 2 trials, representing a key catalyst for potential value appreciation. Positive clinical trial results could significantly increase the company's valuation. However, the company's negative gross margin of -284.9% and negative free cash flow of $-0.00B highlight the significant financial risks associated with investing in a development-stage biotechnology company. The company's beta of 1.87 indicates high volatility relative to the market. Successful development and commercialization of its drug candidates are critical for long-term success, but face significant regulatory and market hurdles.
Based on FMP financials and quantitative analysis
ACHFF Key Highlights
- Lead drug candidate LSALT Peptide is in Phase 2 clinical trials targeting inflammation-related acute kidney injury.
- Developing cilastatin for the prevention of toxin-related acute kidney injury, addressing a different mechanism of kidney damage.
- CKD Platform focused on developing therapeutics for chronic kidney disease, expanding the company's pipeline beyond acute conditions.
- Negative gross margin of -284.9% reflects the high costs associated with drug development and limited revenue generation at this stage.
- Free cash flow of $-0.00B indicates the company's reliance on external funding to support its operations and research activities.
Who Are ACHFF's Competitors?
ACHFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACHFF's Key Strengths?
- Proprietary drug candidates targeting unmet needs in kidney disease.
- Lead drug candidate LSALT Peptide in Phase 2 clinical trials.
- Focus on developing novel therapies for organ damage.
- Experienced management team with expertise in drug development.
What Are ACHFF's Weaknesses?
- Limited financial resources and reliance on external funding.
- Negative gross margin and free cash flow.
- High risk associated with drug development and regulatory approval.
- Small market capitalization and limited trading volume.
What Could Drive ACHFF Stock Higher?
- Phase 2 clinical trial results for LSALT Peptide.
- Development of cilastatin for the prevention of toxin-related AKI.
- Advancement of CKD Platform, therapeutics targeting chronic kidney disease.
- Potential strategic partnerships with larger pharmaceutical companies.
- Regulatory milestones and approvals for drug candidates.
What Are the Key Risks for ACHFF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for its drug candidates.
- Competition from larger pharmaceutical companies with established pipelines.
- Unfavorable clinical trial results.
- Inability to secure funding to support its operations.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for ACHFF?
- Expansion into New Therapeutic Areas: Arch Biopartners has the opportunity to leverage its expertise in kidney disease to expand into related therapeutic areas, such as cardiovascular disease or diabetes. These conditions often contribute to kidney damage, creating synergistic opportunities for drug development. The market for cardiovascular and diabetes therapeutics is substantial, offering significant growth potential. This expansion would require additional research and development investment but could diversify the company's pipeline and reduce its reliance on kidney disease alone. The timeline for this expansion would likely be several years, contingent on the success of its current pipeline.
- Strategic Partnerships and Collaborations: Collaborating with larger pharmaceutical companies or research institutions can provide Arch Biopartners with access to additional resources, expertise, and funding. Strategic partnerships can accelerate the development and commercialization of its drug candidates, reducing the company's financial burden and increasing its chances of success. These partnerships could involve licensing agreements, joint ventures, or co-development arrangements. The timeline for establishing such partnerships is uncertain but could be pursued in the near term to support the advancement of its pipeline.
- Geographic Expansion: While currently focused on Canada, Arch Biopartners can expand its operations into other geographic markets, such as the United States or Europe. These markets offer larger patient populations and greater commercial opportunities. However, geographic expansion would require significant investment in regulatory compliance, marketing, and distribution. The timeline for this expansion would likely be several years, contingent on the success of its drug candidates in clinical trials and regulatory approvals in the target markets.
- Development of Companion Diagnostics: Developing companion diagnostics to identify patients who are most likely to benefit from its therapies can improve treatment outcomes and increase market adoption. Companion diagnostics can help personalize medicine and ensure that patients receive the most appropriate treatment. This would require collaboration with diagnostic companies and investment in research and development. The timeline for developing companion diagnostics would depend on the specific drug candidate and the availability of suitable biomarkers.
- Acquisition of Complementary Technologies or Companies: Arch Biopartners can acquire complementary technologies or companies to expand its pipeline and capabilities. This could involve acquiring companies with promising drug candidates in related therapeutic areas or technologies that enhance drug delivery or target identification. Acquisitions can provide access to new markets, expertise, and intellectual property. However, acquisitions also carry risks, such as integration challenges and financial burdens. The timeline for pursuing acquisitions is uncertain but could be considered as the company grows and generates more revenue.
What Opportunities Does ACHFF Have?
- Positive clinical trial results for LSALT Peptide.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas and geographic markets.
- Development of companion diagnostics to personalize treatment.
What Threats Does ACHFF Face?
- Competition from larger pharmaceutical companies with established pipelines.
- Failure to obtain regulatory approval for its drug candidates.
- Unfavorable clinical trial results.
- Inability to secure funding to support its operations.
What Are ACHFF's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Focus on unmet needs in the treatment of kidney diseases.
- Expertise in developing novel therapies for organ damage.
- Lead drug candidate in Phase 2 clinical trials.
What Does ACHFF Do?
Arch Biopartners Inc., based in Toronto, Canada, is a biotechnology company dedicated to the development of innovative therapies for acute kidney injury (AKI) and organ damage. The company's primary focus is on addressing critical unmet needs in the treatment of kidney diseases. Their lead drug candidate, LSALT Peptide, is currently undergoing Phase 2 clinical trials to evaluate its efficacy in treating inflammation-related AKI experienced by patients undergoing on-pump (bypass) cardiac surgery. This targets a significant complication associated with cardiac surgery, where patients are at risk of developing AKI due to the inflammatory response triggered by the procedure. In addition to LSALT Peptide, Arch Biopartners is also developing cilastatin for the prevention of toxin-related AKI. Cilastatin works by inhibiting dipeptidase-1, an enzyme involved in the metabolism of certain toxins that can damage the kidneys. Furthermore, the company is advancing its CKD Platform, which focuses on developing therapeutics for chronic kidney disease (CKD), a progressive condition affecting millions worldwide. Arch Biopartners operates primarily in Canada, conducting research and development activities to advance its pipeline of drug candidates. The company aims to improve patient outcomes and address the significant healthcare burden associated with kidney diseases through its innovative therapeutic approaches.
What Products and Services Does ACHFF Offer?
- Develop novel drugs for acute kidney injury.
- Develop drugs for organ damage.
- Focus on lead drug candidate LSALT Peptide.
- LSALT Peptide is in Phase 2 trials for inflammation related acute kidney injury.
- Develop cilastatin to prevent toxin related acute kidney injury.
- Develop CKD Platform, therapeutics targeting chronic kidney disease.
How Does ACHFF Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from health authorities, such as Health Canada and the FDA.
- May out-license or partner with larger pharmaceutical companies to commercialize its drugs.
What Industry Does ACHFF Operate In?
Arch Biopartners operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for kidney disease therapeutics is substantial, driven by the increasing prevalence of diabetes, hypertension, and other risk factors. The company faces competition from larger pharmaceutical companies with established pipelines and resources. The success of Arch Biopartners depends on its ability to successfully develop and commercialize its drug candidates, navigate the regulatory landscape, and secure funding to support its operations.
Who Are ACHFF's Key Customers?
- Hospitals and medical centers that treat patients with acute kidney injury.
- Patients undergoing on-pump cardiac surgery who are at risk of developing AKI.
- Patients with chronic kidney disease.
- Pharmaceutical companies that may license or partner with Arch Biopartners to commercialize its drugs.
Company Profile
Arch Biopartners Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Richard Gabriel Muruve. ACHFF has traded publicly since 2002.
F-Score 2/9Financial Health
Arch Biopartners Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 72%Key Financial Metrics
Return on equity for Arch Biopartners Inc. stands at 72.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.
ACHFF Valuation & Market Position
With a $40.58M market cap, Arch Biopartners Inc. sits in the micro-cap segment of the market. Relative to its peer group, ACHFF's quantitative score of 38/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Arch Biopartners Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.16.
ACHFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with the most knowledge of the company see value, potentially signaling confidence in future prospects.
- The community is buzzing about potential breakthroughs in Arch's drug pipeline, creating a positive feedback loop and attracting more attention.
- Market perception seems to be shifting as investors recognize the potential of Arch's technology in addressing unmet medical needs.
- There's a growing sense that Arch is undervalued compared to its peers, making it an attractive acquisition target or a company poised for significant growth.
Bear Case
- Community sentiment is heavily reliant on trial outcomes, making it vulnerable to negative news and potentially triggering a sell-off.
- The company's limited revenue and reliance on future developments create substantial execution risk and uncertainty about long-term viability.
- Market perception is still largely speculative, with many investors waiting for concrete results before committing significant capital.
- Recent insider selling, even if for personal reasons, could raise concerns about the company's prospects and erode investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $158,079 | -$242,334 | -$0.0037 |
Based on FMP financials and quantitative analysis
ACHFF Latest News
-
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
globenewswire.com · Jun 4, 2026
-
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
globenewswire.com · May 22, 2026
ACHFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACHFF.
Price Targets
Wall Street price target analysis for ACHFF.
ACHFF MoonshotScore
What does this score mean?
The MoonshotScore rates ACHFF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
ACHFF OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market for U.S. companies. It is distinguished from the OTC Pink tier by requiring companies to meet certain financial reporting and corporate governance standards. Companies on the OTCQB must be current in their financial reporting, undergo an annual verification process, and meet a minimum bid price test, which is typically a penny stock. This tier offers more visibility and credibility compared to the OTC Pink, but it still carries more risk than trading on a major exchange like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can make it difficult to buy or sell shares.
- Lower reporting standards compared to major exchanges.
- Greater price volatility due to lower trading volume.
- Potential for delisting if the company fails to meet OTCQB requirements.
- Increased risk of fraud or manipulation compared to major exchanges.
- Verify the company's financial statements and SEC filings.
- Review the company's management team and board of directors.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor the company's news and press releases.
- Consult with a financial advisor.
- Current in financial reporting to OTC Markets.
- Adherence to OTCQB listing requirements.
- Active investor relations and communication.
- Independent board members.
- Audited financial statements.
Common Questions About ACHFF (Healthcare)
What does Arch Biopartners Inc. do?
Arch Biopartners Inc. is a biotechnology company focused on developing novel therapies for acute kidney injury (AKI) and organ damage. Their lead drug candidate, LSALT Peptide, is currently in Phase 2 clinical trials for treating inflammation-related AKI in patients undergoing cardiac surgery. The company is also developing cilastatin to prevent toxin-related AKI and has a CKD Platform for developing therapeutics for chronic kidney disease. Arch Biopartners aims to address significant unmet needs in the treatment of kidney diseases through its innovative therapeutic approaches.
What do analysts say about ACHFF stock?
As of March 16, 2026, there is no readily available analyst coverage specifically for ACHFF stock due to its OTCQB listing and small market capitalization. Consequently, there is no consensus rating or price target available. Investment decisions should be based on individual risk tolerance, thorough due diligence, and an understanding of the inherent risks associated with investing in early-stage biotechnology companies. Investors should carefully review the company's financial statements, clinical trial data, and regulatory filings before making any investment decisions.
What are the main risks for ACHFF?
Investing in Arch Biopartners Inc. carries significant risks inherent to the biotechnology industry and its status as an OTC-listed company. Key risks include the uncertainty of clinical trial outcomes, the potential for regulatory setbacks, competition from larger pharmaceutical companies, and the company's reliance on external funding. The company's negative gross margin and free cash flow highlight its financial vulnerability. Additionally, the low liquidity of ACHFF stock on the OTCQB market can lead to price volatility and difficulty in executing trades. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for ACHFF?
Arch Biopartners Inc. (ACHFF) holds an AI score of 38/100 (low). Not financial advice.
How frequently does ACHFF data refresh on this page?
ACHFF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACHFF's recent stock price performance?
Arch Biopartners Inc. (ACHFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates targeting unmet needs in kidney disease. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACHFF overvalued or undervalued right now?
Valuing Arch Biopartners Inc. (ACHFF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACHFF?
Before investing in Arch Biopartners Inc. (ACHFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may have limited reliability compared to major exchanges.
- Analyst coverage may be limited due to the company's size and listing.